Bharati Mehani

Preprint describing CSI-TME, a framework that models prognostic interactions between cell states in IDH‑mutant gliomas and links interactions to clinical outcome and response to immune checkpoint blockade.

Multi‑platform integrative genomic and epigenomic analysis identifying two MPNST subgroups with distinct transcriptional networks and potential therapeutic vulnerabilities (SHH and WNT pathway activations); Mehani is a co‑contributor on the study.

Study using CIBERSORTx and single-cell derived signature matrices to estimate immune cell type–specific gene expression in large glioma datasets; identifies immune cell signatures associated with IDH status, malignant cell states and patient outcomes.

Analysis of fusion transcripts across human cortex and single-cell transcriptomes showing age-associated increases and distinct genomic features; Mehani contributed to data analysis and validation experiments.